Evidence map›Paper›PMID 28768369›Full record

ReviewAnnals of the New York Academy of Sciences2018

Recent developments in understanding the role of the gut microbiota in brain health and disease.

Eoin Sherwin, Timothy G Dinan, John F Cryan

2 registry-linked trialsAbstract readReview
PubMed Publisher
In one paragraph

Review in Annals of the New York Academy of Sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 152 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
152citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04841668 completedstarted 2021, after this paper: background citation

Gut-Brain-axis: Targets for Improvement of Cognition in the Elderly

Ran2021Enrolled50Registered outcomes51Posted comparisons0ConditionsType 2 Diabetes MellitusArmsMetformin
Open the trial in the graph
NCT05601856 unknown statusnot on this mapstarted 2022, after this paper: background citation

Gut Microbiome and Blood Indices in Patients With AD and Their Spousal Caregivers

TypeobservationalSponsorUniversity of VirginiaRan2022 to 2025Enrolled104ConditionsAlzheimer Disease, Gut Biome
3 · Its place in the literature

Who cites it

152 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Review
  5. Article
  6. Efavirenz-Altered Gut-Microbiota,International journal of molecular sciences · 2026
    Article
  7. Article
  8. Review
  9. [ModifiedNan fang yi ke da xue xue bao = Journal of Southern Medical University · 2026
    Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. [Mechanisms by which the gut microbiota regulates depressive disorder via the tryptophan metabolic pathway].Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2025
    Review
  16. Review
  17. Article
  18. Review
  19. Fruit-Based Diet and Gut Health: A Review.Food science & nutrition · 2025
    Review
  20. Article

92 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Eoin SherwinAPC Microbiome Institute, University College Cork, Cork, Ireland.
Timothy G DinanAPC Microbiome Institute, University College Cork, Cork, Ireland.
John F CryanAPC Microbiome Institute, University College Cork, Cork, Ireland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There is a growing appreciation of the role of the gut microbiota in all aspects of health and disease, including brain health. Indeed, roles for the bacterial commensals in various psychiatric and neurological conditions, such as depression, autism, stroke, Parkinson's disease, and Alzheimer's disease, are emerging. Microbiota dysregulation has been documented in all of these conditions or in animal models thereof. Moreover, depletion or modulation of the gut microbiota can affect the severity of the central pathology or behavioral deficits observed in a variety of brain disorders. However, the mechanisms underlying such effects are only slowly being unraveled. Additionally, recent preclinical and clinical evidence suggest that targeting the microbiota through prebiotic, probiotic, or dietary interventions may be an effective "psychobiotic" strategy for treating symptoms in mood, neurodevelopmental disorders, and neurodegenerative diseases.

Indexed as

AgingBrainDysbiosisGastrointestinal MicrobiomeHumansNeurodegenerative DiseasesNeurodevelopmental DisordersPrebioticsProbioticsPrebioticsagingbehaviorbraindietmicrobiotaneurodegeneration

Identifiers

PMID28768369

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.